Press coverage about Dimension Therapeutics (NASDAQ:DMTX) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dimension Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3084033641082 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities analysts have recently commented on DMTX shares. Chardan Capital reiterated a “hold” rating on shares of Dimension Therapeutics in a research note on Monday, August 14th. Canaccord Genuity lowered Dimension Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $12.00 to $3.41 in a research note on Wednesday, August 30th. Citigroup Inc. lowered Dimension Therapeutics from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $3.41 to $5.50 in a research note on Tuesday, September 19th. ValuEngine upgraded Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Finally, Wells Fargo & Company lowered Dimension Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Dimension Therapeutics currently has an average rating of “Hold” and a consensus target price of $5.08.
Dimension Therapeutics (DMTX) remained flat at $$5.95 during trading on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 3.33. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $6.10.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.